Cargando…

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition

BACKGROUND: Malignant melanoma is an aggressive tumor type that often develops drug resistance to targeted therapeutics. The production of colony stimulating factor 1 (CSF-1) in tumors recruits myeloid cells such as M2-polarized macrophages and myeloid derived suppressor cells (MDSC), leading to an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mok, Stephen, Tsoi, Jennifer, Koya, Richard C, Hu-Lieskovan, Siwen, West, Brian L, Bollag, Gideon, Graeber, Thomas G, Ribas, Antoni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432503/ https://www.ncbi.nlm.nih.gov/pubmed/25939769 http://dx.doi.org/10.1186/s12885-015-1377-8

Ejemplares similares

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Exosomes as a predictor tool of acquired resistance to melanoma treatment
por: Goedert, Lucas, et al.
Publicado: (2014)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma
por: Titz, Bjoern, et al.
Publicado: (2016)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

VEGF blockade enhances the antitumor effect of BRAF(V) (600E) inhibition
por: Comunanza, Valentina, et al.
Publicado: (2016)

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
por: Moser, Justin C., et al.
Publicado: (2019)

Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
por: Crespo-Rodriguez, Eva, et al.
Publicado: (2020)

Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer
por: Zhang, Jingxin, et al.
Publicado: (2017)

RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF
por: Poulikakos, Poulikos I., et al.
Publicado: (2010)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials
por: Liu, Mengdong, et al.
Publicado: (2017)

Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas
por: Yan, D, et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

BRAF Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition
por: Campos, Maira P., et al.
Publicado: (2018)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Autophagy Inhibition in BRAF-Driven Cancers
por: Foth, Mona, et al.
Publicado: (2021)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure
por: Shin, Daniel, et al.
Publicado: (2015)

MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor
por: Caenepeel, Sean, et al.
Publicado: (2017)

Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma
por: Benedicto, Aitor, et al.
Publicado: (2021)

Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice
por: Dagher, Nabil N., et al.
Publicado: (2015)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition
por: Yeom, Hojin, et al.
Publicado: (2021)

SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF
por: Feng, Kai, et al.
Publicado: (2022)

Colony stimulating factors secreted by irradiated autologous tumor cell vaccines inhibit immunity
por: Ravindranathan, Sruthi, et al.
Publicado: (2015)

Central inhibition of granulocyte-macrophage colony-stimulating factor is analgesic in experimental neuropathic pain
por: Nicol, Louise S.C., et al.
Publicado: (2018)

BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
por: Cooper, Zachary A, et al.
Publicado: (2013)

The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
por: Sánchez-Tilló, Ester, et al.
Publicado: (2023)

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
por: Mulcahy Levy, Jean M, et al.
Publicado: (2017)

BRAF Inhibition in BRAF(V600)-Mutant Gliomas: Results From the VE-BASKET Study
por: Kaley, Thomas, et al.
Publicado: (2018)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

BRAF inhibition protects against hearing loss in mice
por: Ingersoll, Matthew A., et al.
Publicado: (2020)

BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?
por: Bouchè, Victoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8n7nddc44ccen6r8qdvm15ruls